EPHA2 and cancer: More recently, the ability of an anti-EphA2 BiTE secreted by retrovirally transduced primary T cells demonstrated the ability of STAb-T cells to redirect the cytotoxic activity of non-transduced T cells specifically to EphA2+ cancer cells in vitro and showed potent anti-tumor activity in vivo (41).